BSX
Boston Scientific Corporation
BSX's fundamentals are strong and it looks cheap: trading at 19x earnings, about a third of its usual 64x. Analysts expect earnings to hold roughly steady.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
BSX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Stable |
BSX's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
BSX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $44.20 | — |
| Cheap | 18x | $43.27 | -2.1% |
| Current | 19x | $44.20 | — |
| Fair | 64x | $151 | +241% |
| Expensive | 90x | $211 | +378% |
Historical ranges are pointers, not guarantees.
BSX's PE is in its cheap range at 19x. On analysts' estimates for next year's earnings, today's price would be 14x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
BSX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Stable | |
| Stable | |
| Stable | |
| Moderate | |
| High |
Analysts expect BSX's earnings, revenue and profitability to hold roughly steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
BSX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.09 | +31% |
| Q3 2026 | $2.36 | +26% |
| Q2 2026 | $2.47 | +47% |
| Q1 2026 | $2.39 | +74% |
| Q4 2025 | $1.94 | +55% |
| Q3 2025 | $1.87 | +55% |
| Q2 2025 | $1.68 | +37% |
| Q1 2025 | $1.37 | +15% |
| Q4 2024 | $1.25 | +17% |
BSX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
BSX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +1.4% |
| Q2 2026 | $5.4B | +7.5% |
| Q1 2026 | $5.2B | +12% |
| Q4 2025 | $5.3B | +16% |
| Q3 2025 | $5.1B | +20% |
| Q2 2025 | $5.1B | +23% |
| Q1 2025 | $4.7B | +21% |
| Q4 2024 | $4.6B | +22% |
BSX's revenue has grown year over year for 23 quarters in a row: $5.1B last quarter, up 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -4.6 points |
| Q2 2026 | 22% | +5.5 points |
| Q1 2026 | 21% | +1.4 points |
| Q4 2025 | 16% | +0.8 points |
| Q3 2025 | 21% | +3.3 points |
| Q2 2025 | 16% | +3.6 points |
| Q1 2025 | 20% | +2.2 points |
| Q4 2024 | 15% | -0.9 points |
BSX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over BSX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
BSX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $868M | -25% |
| Q2 2026 | $1.3B | +13% |
| Q1 2026 | $171M | -52% |
| Q4 2025 | $1B | -14% |
| Q3 2025 | $1.2B | +41% |
| Q2 2025 | $1.1B | +72% |
| Q1 2025 | $354M | +$369M |
| Q4 2024 | $1.2B | +71% |
BSX generated $3.3B in free cash flow over the past year, down 13% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over BSX on cash flow, with more consistent year-over-year improvement.
BSX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -22.8M shares |
| 1 year | -2.9% | -43.5M shares |
| 3 years | -1.6% | -23M shares |
| 5 years | +1.1% | +16.4M shares |
| Available history | +2.9% | +41.4M shares |
BSX has 1.5B diluted shares, down 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over BSX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
BSX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.2x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.9x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.6x | Moderate |
| Q4 2024 | 2.7x | Moderate |
BSX's net debt is about 2.1 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
BSX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.6 | Neutral |
| Stochastic | 25.4 | Neutral |
BSX's weekly RSI is 40 (neutral) and its Stochastic is 25 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
BSX PE vs Healthcare Sector
| Metric | BSX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 17 | 29 | 12 pts below |
BSX is trading at 19x earnings, a 28% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
BSX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.5 | 1.5% above |
| 20 week MA | $45.3 | 2.4% below |
| 50 week MA | $60.8 | 27% below |
| 100 week MA | $80.8 | 45% below |
| 200 week MA | $72.2 | 39% below |
BSX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
BSX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.2 | $34.6 | -24% |
| 2021 | $34.6 | $42.7 | +24% |
| 2022 | $42.7 | $46.1 | +7.8% |
| 2023 | $46.1 | $57.8 | +26% |
| 2024 | $57.8 | $90.7 | +57% |
| 2025 | $90.7 | $96.1 | +6% |
| 2026 YTD | $96.1 | $44.2 | -54% |
BSX is down 54% so far in 2026, after finishing higher in five of the previous six years.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over BSX on returns for 2026, with the stronger performance.